Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05462353
PHASE2

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Sponsor: Gannex Pharma Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a Phase 2, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults with Nonalcoholic Steatohepatitis (NASH).

Official title: A Phase II, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

183

Start Date

2022-09-30

Completion Date

2025-06-10

Last Updated

2025-01-08

Healthy Volunteers

No

Interventions

DRUG

2mg of ASC41

ASC41 tablet administered orally once daily.

DRUG

4mg of ASC41 (2 tablets of 2 mg ASC41)

ASC41 tablets administered orally once daily.

DRUG

Placebo

Placebo tablets administered orally once daily.

Locations (1)

The affiliated Hospital of Hangzhou Normal University

Hangzhou, Zhejiang, China